LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.

    Hsieh, H-Y / Jou, Y-C / Tung, C-L / Tsai, Y-S / Wang, Y-H / Chi, C-L / Lin, R-I / Hung, S-K / Chuang, Y-M / Wu, S-F / Li, C / Shen, C-H / Chan, M W Y / Hsu, C-D

    Oncogene

    2017  Volume 37, Issue 5, Page(s) 673–686

    Abstract: Urothelial carcinoma (UC) carcinogenesis has been hypothesized to occur through epigenetic repression of tumor-suppressor genes (TSGs). By quantitative real-time polymerase chain reaction array, we found that one potential TSG, angiopoietin-like 4 ( ... ...

    Abstract Urothelial carcinoma (UC) carcinogenesis has been hypothesized to occur through epigenetic repression of tumor-suppressor genes (TSGs). By quantitative real-time polymerase chain reaction array, we found that one potential TSG, angiopoietin-like 4 (ANGPTL4), was expressed at very low levels in all bladder cancer cell lines we examined. Previous studies had demonstrated that ANGPTL4 is highly expressed in some cancers, but downregulated, by DNA methylation, in others. Consequently, owing to these seemingly conflicting functions in distinct cancers, the precise role of ANGPTL4 in the etiology of UC remains unclear. In this study, using methylation-specific PCR and bisulfite pyrosequencing, we show that ANGPTL4 is transcriptionally repressed by DNA methylation in UC cell lines and primary tumor samples, as compared with adjacent noncancerous bladder epithelium. Functional studies further demonstrated that ectopic expression of ANGPTL4 potently suppressed UC cell proliferation, monolayer colony formation in vitro, and invasion, migration, and xenograft formation in vivo. Surprisingly, circulating ANGPTL4 was significantly higher in plasma samples from UC patients than normal control, suggesting it might be secreted from other cell types. Interestingly, our data also indicated that exogenous cANGPTL4 could promote cell proliferation and cell migration via activation of signaling through the Erk/focal adhesion kinase axis. We further confirmed that mouse xenograft tumor growth could be promoted by administration of exogenous cANGPTL4. Finally, immunohistochemistry demonstrated that ANGPTL4 was downregulated in tumor cells but overexpressed in tumor adjacent stromal tissues of muscle-invasive UC tissue samples. In conclusion, our data support dual roles for ANGPTL4 in UC progression, either as a tumor suppressor or oncogene, in response to microenvironmental context.
    MeSH term(s) Aged ; Aged, 80 and over ; Angiopoietin-like 4 Protein/blood ; Angiopoietin-like 4 Protein/genetics ; Angiopoietin-like 4 Protein/metabolism ; Animals ; Carcinogenesis/genetics ; Carcinoma, Transitional Cell/genetics ; Carcinoma, Transitional Cell/pathology ; Carcinoma, Transitional Cell/surgery ; Case-Control Studies ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Proliferation/genetics ; Cystectomy ; DNA Methylation/genetics ; Down-Regulation ; Epigenesis, Genetic/genetics ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Genes, Tumor Suppressor ; Humans ; Male ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Middle Aged ; Oncogenes/genetics ; Promoter Regions, Genetic/genetics ; Signal Transduction ; Tumor Microenvironment ; Urinary Bladder/pathology ; Urinary Bladder/surgery ; Urinary Bladder Neoplasms/genetics ; Urinary Bladder Neoplasms/pathology ; Urothelium/pathology ; Xenograft Model Antitumor Assays
    Chemical Substances ANGPTL4 protein, human ; Angiopoietin-like 4 Protein
    Language English
    Publishing date 2017-10-16
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639046-8
    ISSN 1476-5594 ; 0950-9232
    ISSN (online) 1476-5594
    ISSN 0950-9232
    DOI 10.1038/onc.2017.375
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: A simple means of making the differential diagnosis of ureterouterine and vesicouterine fistula.

    Sheen, J H / Lin, C T / Jou, Y C / Cheng, M T

    The Journal of urology

    1998  Volume 160, Issue 4, Page(s) 1420–1421

    MeSH term(s) Adult ; Cesarean Section/adverse effects ; Diagnosis, Differential ; Female ; Fistula/diagnostic imaging ; Fistula/etiology ; Humans ; Radiography ; Ureteral Diseases/diagnostic imaging ; Ureteral Diseases/etiology ; Urinary Bladder Fistula/diagnostic imaging ; Urinary Bladder Fistula/etiology ; Urinary Fistula/diagnostic imaging ; Urinary Fistula/etiology ; Uterine Diseases/diagnostic imaging ; Uterine Diseases/etiology
    Language English
    Publishing date 1998-10
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Role of cyclic adenosine monophosphate in prostaglandin E1-induced penile erection in rabbits.

    Lin, J S / Lin, Y M / Jou, Y C / Cheng, J T

    European urology

    1995  Volume 28, Issue 3, Page(s) 259–265

    Abstract: To investigate the role of cyclic adenosine monophosphate (cAMP) in penile erection in relation to the effect of prostaglandin E1 (PGE1) male adult New Zealand white rabbits were utilized as a model to study intracavernous pressure (ICP) in vivo. After ... ...

    Abstract To investigate the role of cyclic adenosine monophosphate (cAMP) in penile erection in relation to the effect of prostaglandin E1 (PGE1) male adult New Zealand white rabbits were utilized as a model to study intracavernous pressure (ICP) in vivo. After intracavernous injection of PGE1 (0.2-1.6 micrograms/kg) and 8-bromocyclic adenosine monophosphate (8-Br-cAMP, 0.5-1.5 mg/kg), both drugs raised the ICP in a dose-dependent manner. The increased ICPs induced by PGE1 and 8-Br-cAMP were 33.4 +/- 8.12 and 24.1 +/- 4.9 mm Hg, respectively (p < 0.05, paired Student's t test). Administrations of cyclic adenosine monophosphothioate, Rp-isomer (cAMP antagonist, 0.02-0.08 mumol/kg) prior to PGE1 injections inhibited the effect of PGE1 in vivo in a dose-dependent manner. The systemic blood pressures and heart rates in rabbits were unchanged during all the intracavernous injections. The corpus cavernosal tissues isolated from rabbits were studied for the cAMP contents after incubation of different doses of PGE1 in vitro. The cAMP contents were also elevated in a manner parallel with the increases in PGE1 concentrations (3-9 microM). We conclude: (1) the feasibility of intracavernous injection of vasoactive drugs is similar to that in man, thus the rabbit can be used as a suitable alternative for the studies of penile erection, and (2) cAMP is mediated in PGE1-induced relaxation of the rabbit corpus cavernosum, and the cAMP system only participates partially in penile erection.
    MeSH term(s) 8-Bromo Cyclic Adenosine Monophosphate/pharmacology ; Alprostadil/pharmacology ; Animals ; Cyclic AMP/analogs & derivatives ; Cyclic AMP/analysis ; Cyclic AMP/physiology ; Dose-Response Relationship, Drug ; Male ; Muscle Relaxation/drug effects ; Papaverine/pharmacology ; Penile Erection/drug effects ; Penile Erection/physiology ; Penis/chemistry ; Penis/physiology ; Pressure ; Rabbits
    Chemical Substances 8-Bromo Cyclic Adenosine Monophosphate (23583-48-4) ; Papaverine (DAA13NKG2Q) ; Cyclic AMP (E0399OZS9N) ; Alprostadil (F5TD010360)
    Language English
    Publishing date 1995
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 193790-x
    ISSN 1421-993X ; 0302-2838
    ISSN (online) 1421-993X
    ISSN 0302-2838
    DOI 10.1159/000475062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: long-term durability with Prostcare.

    Tsai, Y S / Lin, J S / Tong, Y C / Tzai, T S / Yang, W H / Chang, C C / Cheng, H L / Lin, Y M / Jou, Y C

    European urology

    2001  Volume 39, Issue 6, Page(s) 688–92; discussion 693–4

    Abstract: Objective: To evaluate the long-term durability of transurethral microwave thermotherapy (TUMT) with Prostcare for symptomatic benign prostatic hyperplasia (BPH).: Patients and methods: From August 1993 to July 1994, a total of 65 patients with ... ...

    Abstract Objective: To evaluate the long-term durability of transurethral microwave thermotherapy (TUMT) with Prostcare for symptomatic benign prostatic hyperplasia (BPH).
    Patients and methods: From August 1993 to July 1994, a total of 65 patients with symptomatic BPH who underwent TUMT using the Prostcare apparatus (Bruker Spectospin, Wissembourg, France) with low-energy protocol (maximal power 52 W) were enrolled into a short-term evaluation. Subsequent follow-up information was collected in July 1999. If patients had had any further therapy for BPH, the date of retreatment was considered as an endpoint of TUMT efficacy. If no further therapy for BPH had been needed, they were re-assessed for overall satisfaction.
    Results: The median follow-up period was 49 months. Twenty patients were excluded for various reasons, including 17 with loss of follow-up and 3 with new diseases that could affect the voiding status. Thirty-eight (84.4%) of 45 valuable patients had received further therapy for BPH, including medication (n = 21, 46.7%), and endoscopic surgery (n = 17, 37.7%). The times to pharmacologic or endoscopic retreatment after TUMT were 8.9+/-11.1 and 23.0+/-14.4 months, respectively (p = 0.0003, log rank test). Only 7 (15.5%) patients had no further treatment, with 3 having satisfactory improvements, but 4 feel dissatisfied yet not needing any further therapy. In addition, 2 patients complained of erectile dysfunction after TUMT and 1 was diagnosed with prostate cancer 50 months after TUMT. In addition, there was no significant difference for all baseline values among three groups with no retreatment or retreatment with medication or endoscopic surgery.
    Conclusion: At the 5-year follow-up, the long-term durability of low-energy TUMT with Prostcare is only exhibited in a few patients and the overall retreatment rate was 84.4%. Thus, patient should be informed of the high probability of supplementary treatment after TUMT.
    MeSH term(s) Aged ; Follow-Up Studies ; Humans ; Hyperthermia, Induced ; Male ; Microwaves/therapeutic use ; Patient Satisfaction ; Prostatic Hyperplasia/therapy ; Time Factors
    Language English
    Publishing date 2001-06
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 193790-x
    ISSN 1421-993X ; 0302-2838
    ISSN (online) 1421-993X
    ISSN 0302-2838
    DOI 52528
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: short-term experience with Prostcare.

    Tsai, Y S / Lin, J S / Tong, Y C / Tzai, T S / Yang, W H / Chang, C C / Cheng, H L / Lin, Y M / Jou, Y C

    Urologia internationalis

    2000  Volume 65, Issue 2, Page(s) 89–94

    Abstract: Purpose: To assess our short-term experience with transurethral microwave thermotherapy (TUMT) for symptomatic benign prostatic hyperplasia (BPH).: Patients and methods: From August 1993 through July 1994, in total 65 patients with symptomatic BPH ... ...

    Abstract Purpose: To assess our short-term experience with transurethral microwave thermotherapy (TUMT) for symptomatic benign prostatic hyperplasia (BPH).
    Patients and methods: From August 1993 through July 1994, in total 65 patients with symptomatic BPH were enrolled into this study. The patients' ages ranged from 56 to 95 years with a mean of 70 years. Under local anesthesia with intraurethral instillation of Xylocaine jelly only, all patients received one session of TUMT for up to 60 min with Prostcare equipment. Uroflowmetry was performed and international prostatic symptom score (IPSS) determined before 3 and 6 months after TUMT for assessment of efficacy. All adverse events were recorded and evaluated for clinical relevance.
    Results: At 3 and 6 months following TUMT, the mean IPSS decreased from 19.7 +/- 6.8 (baseline) to 12.8 +/- 8.2 (-46%) and to 15.5 +/- 9.0 (-21%), respectively; the maximal urine flow rate at 3 and 6 months increased from 9.1 +/- 4.8 ml/s (baseline) to 11.0 +/- 4.9 ml/s (+21%) and to 10.9 +/- 5.6 ml/s (+19%), respectively. During TUMT, burning sensation was the most frequent complaint (38.5%), followed by urethral discomfort (29.2%) and urgency (9.2%). Two patients (3.1%) interrupted TUMT, because of intolerable pain. Following TUMT micturition pain (73.8%) and gross hematuria (45.9%) were the most adverse events. Most of these adverse events disappeared within 2 weeks. One patient suffered from skin erosion over the penoscrotal junction 1 week later. None had retrograde ejaculation; 1 patient complained of erectile dysfunction.
    Conclusion: Although the efficacy of TUMT with Prostcare became less prominent 6 months after TUMT, TUMT was still a tolerable, safe alternative treatment of BPH, especially in patients who were not suitable for transurethral resection of the prostate or anesthesia.
    MeSH term(s) Aged ; Aged, 80 and over ; Diathermy/methods ; Humans ; Male ; Microwaves/therapeutic use ; Middle Aged ; Prostatic Hyperplasia/physiopathology ; Prostatic Hyperplasia/therapy ; Time Factors ; Urethra ; Urodynamics
    Language English
    Publishing date 2000
    Publishing country Switzerland
    Document type Clinical Trial ; Journal Article
    ZDB-ID 204045-1
    ISSN 1423-0399 ; 0042-1138
    ISSN (online) 1423-0399
    ISSN 0042-1138
    DOI 10.1159/000064846
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top